What is the current stock price of Genelux Corporation (GNLX)?

As of the latest market data, Genelux Corporation (GNLX) is trading at $3.06. The stock has seen a gain of 1.66% today.

Does Genelux Corporation (GNLX) pay a dividend?

Based on current data, Genelux Corporation does not have a confirmed active dividend policy.

What is the market cap of Genelux Corporation?

The current market capitalization of Genelux Corporation (GNLX) is approximately unavailable.

GNLX

Genelux Corporation·Healthcare

3.06

1.661%(+0.05)

Close Price

3.28

7.190%(+0.22)

After Hours

Last Updated: — ET

52W L: $2.2952W H: $8.54

GNLX NEWS

globenewswire.com

May 7

Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates

-- Topline data from randomized Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Systemic lung cancer programs advancing with additional updates expected throughout 2026 -- -- $26.3 million in cash, cash equivalents, marketable securities and restricted cash as of March 31, 2026; expected to fund operations into 1Q27 -- WESTLAKE VILLAGE, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter of 2026 and provided general business updates.

globenewswire.com

Mar 19

Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

-- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Interim systemic lung cancer data with Olvi-Vec demonstrated partial responses in relapsed small cell lung cancer (SCLC) and early signs of anti-tumor activity in non-small cell lung cancer (NSCLC); additional updates expected throughout 2026 --

Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2023-01-26

Beta

0.50

Websitewww.genelux.com↗